Holen Sie sich die Stockscreener-App
26.62
1.48%
-0.4836
Schlusskurs vom Vortag:
$27.10
Offen:
$26.66
24-Stunden-Volumen:
713.78K
Relative Volume:
0.30
Marktkapitalisierung:
$2.70B
Einnahmen:
$352.57M
Nettoeinkommen (Verlust:
$-143.01M
KGV:
-14.71
EPS:
-1.81
Netto-Cashflow:
$-153.40M
1W Leistung:
+14.25%
1M Leistung:
+20.22%
6M Leistung:
+46.95%
1J Leistung:
-2.96%
1-Tages-Spanne:
$26.12
$27.13
1-Wochen-Bereich:
$23.30
$29.16
52-Wochen-Spanne:
$13.53
$35.25
Beam Therapeutics Inc Stock (BEAM) Company Profile
Firmenname
Beam Therapeutics Inc
Sektor
Branche
Telefon
857-327-8775
Adresse
26 LANDSDOWNE STREET, CAMBRIDGE, MA
Vergleichen Sie BEAM mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BEAM
Beam Therapeutics Inc
|
26.62 | 2.75B | 352.57M | -143.01M | -153.40M | -1.81 |
|
VRTX
Vertex Pharmaceuticals Inc
|
437.92 | 112.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
699.15 | 73.91B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
418.13 | 56.81B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
893.47 | 55.46B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
193.88 | 41.92B | 447.02M | -1.18B | -906.14M | -6.1812 |
Beam Therapeutics Inc Stock (BEAM) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-09 | Eingeleitet | Jefferies | Buy |
| 2025-03-28 | Hochstufung | BofA Securities | Neutral → Buy |
| 2025-03-10 | Hochstufung | Scotiabank | Sector Perform → Sector Outperform |
| 2025-01-29 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2024-11-06 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-10-16 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-07-23 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-01-29 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2023-12-15 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-12-08 | Herabstufung | Jefferies | Buy → Hold |
| 2023-10-20 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2023-10-20 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2023-03-21 | Eingeleitet | Bernstein | Mkt Perform |
| 2023-02-01 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-12-20 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2022-12-13 | Eingeleitet | Citigroup | Buy |
| 2022-06-17 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2022-04-28 | Eingeleitet | Credit Suisse | Neutral |
| 2022-01-05 | Eingeleitet | Guggenheim | Buy |
| 2021-10-19 | Eingeleitet | SVB Leerink | Outperform |
| 2021-09-24 | Fortgesetzt | Stifel | Buy |
| 2021-09-10 | Eingeleitet | BofA Securities | Buy |
| 2021-05-11 | Eingeleitet | Redburn | Buy |
| 2021-05-04 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2021-03-01 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2021-02-16 | Eingeleitet | Wells Fargo | Overweight |
| 2021-01-29 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2021-01-06 | Eingeleitet | Stifel | Hold |
| 2020-08-05 | Eingeleitet | William Blair | Outperform |
| 2020-03-02 | Eingeleitet | Barclays | Overweight |
| 2020-03-02 | Eingeleitet | JP Morgan | Overweight |
| 2020-03-02 | Eingeleitet | Jefferies | Buy |
| 2020-03-02 | Eingeleitet | Wedbush | Outperform |
Alle ansehen
Beam Therapeutics Inc Aktie (BEAM) Neueste Nachrichten
JonesTrading Maintains Beam Therapeutics(BEAM.US) With Buy Rating, Maintains Target Price $35 - 富途牛牛
ASH: Beam Can Rival Vertex In Sickle Cell But Bulsufan Deaths Cast A Shadow - Citeline News & Insights
Beam Therapeutics edges higher after new sickle cell therapy results - MSN
Beam Therapeutics stock rises on promising sickle cell therapy data By Investing.com - Investing.com UK
Beam Therapeutics stock rises on promising sickle cell therapy data - Investing.com
(BEAM) Price Dynamics and Execution-Aware Positioning - news.stocktradersdaily.com
Beam Therapeutics (BEAM) Reveals Positive Trial Results at Hemat - GuruFocus
Beam Therapeutics (BEAM): Reassessing Valuation After New BEACON Sickle Cell Trial Results and Renewed Momentum - Yahoo Finance
Beam Therapeutics (BEAM) Is Up 6.9% After New BEACON Trial Data Spotlight Base-Editing Potential - Yahoo Finance
Beam reports positive data from sickle cell disease gene therapy trial By Investing.com - Investing.com South Africa
Beam reports positive data from sickle cell disease gene therapy trial - Investing.com
Beam Therapeutics Reports Updated Data from BEACON Phase 1/2 Trial of ristoglogene autogetemcel (risto-cel) Highlighting Durable, Differentiated Profile in Sickle Cell Disease (SCD) at American Society of Hematology (ASH) Annual Meeting - The Manila Times
Beam Therapeutics Reports Promising Updates on Risto-cel for Sickle Cell Disease at 67th ASH Annual Meeting - Quiver Quantitative
38,438 Shares in Beam Therapeutics Inc. $BEAM Purchased by Capital Fund Management S.A. - MarketBeat
Beam Therapeutics stock surges 64% since InvestingPro’s April undervalued call By Investing.com - Investing.com Australia
BEAM (Beam Therapeutics) Capex-to-Operating-Income : 0.00 (As of Sep. 2025) - GuruFocus
How Beam Therapeutics Inc. stock compares to industry benchmarksProfit Target & AI Powered Market Entry Strategies - Newser
Beam Therapeutics (BEAM) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Beam Therapeutics: Strong Buy On BEAM-101 Progress And In Vivo LNP Shots On Goal - Seeking Alpha
Beam Therapeutics (NASDAQ:BEAM) Stock Price Up 6.8%What's Next? - MarketBeat
Why Is Beam Therapeutics (BEAM) Up 15.9% Since Last Earnings Report? - Yahoo Finance
Published on: 2025-12-04 06:37:06 - Newser
Why analysts remain bullish on Beam Therapeutics Inc. stockJuly 2025 Trends & Community Verified Trade Signals - Newser
Beam Therapeutics Earnings Notes - Trefis
Beam Therapeutics (BEAM) Experiences Significant Stock Surge - GuruFocus
Will Beam Therapeutics Inc. stock split again soonSell Signal & Daily Volume Surge Trade Alerts - Newser
Will Beam Therapeutics Inc. stock pay special dividends2025 Stock Rankings & Precise Swing Trade Entry Alerts - Newser
Is Beam Therapeutics Inc. stock attractive for ETFsRate Cut & Safe Entry Point Identification - Newser
Beam Therapeutics Advances BEAM-302 Study for AATD: Key Insights for Investors - MSN
Geode Capital Management LLC Grows Position in Beam Therapeutics Inc. $BEAM - MarketBeat
14,601 Shares in Beam Therapeutics Inc. $BEAM Bought by Entropy Technologies LP - MarketBeat
BEAM vs. NTLA: Which Gene Editing Stock Holds More Potential? - sharewise.com
Beam Therapeutics (BEAM) Earnings Transcript - Nasdaq
How resilient is Beam Therapeutics Inc. stock in market downturnsOil Prices & Stepwise Swing Trade Plans - BỘ NỘI VỤ
Beam Therapeutics (NASDAQ:BEAM) Earns Outperform Rating from Analysts at Evercore ISI - MarketBeat
Is Beam Therapeutics Inc. stock a defensive play in 20252025 Winners & Losers & Free Technical Pattern Based Buy Signals - BỘ NỘI VỤ
(BEAM) as a Liquidity Pulse for Institutional Tactics - news.stocktradersdaily.com
ETFs Investing in Beam Therapeutics Inc. Stocks - TradingView
Evercore ISI Group Initiates Coverage of Beam Therapeutics (BEAM) with Outperform Recommendation - MSN
Beam Therapeutics (BEAM) Receives New 'Outperform' Rating from E - GuruFocus
Beam Therapeutics’ BEAM-101 Shows Promising Results in Sickle Cell Disease Trial - MSN
How Beam Therapeutics Inc. stock valuations compare to rivals - newser.com
Analyzing drawdowns of Beam Therapeutics Inc. with statistical toolsAnalyst Upgrade & Growth Oriented Trading Recommendations - newser.com
Is Beam Therapeutics Inc. stock supported by innovation pipeline2025 Key Lessons & Capital Efficiency Focused Strategies - newser.com
How Beam Therapeutics Inc. stock compares to market leaders2025 Biggest Moves & AI Powered Buy/Sell Recommendations - newser.com
Beam Therapeutics (BEAM) Strengthens Cash Position as Key Trials Move Forward - MSN
Historical volatility pattern of Beam Therapeutics Inc. visualized2025 Valuation Update & Reliable Volume Spike Trade Alerts - newser.com
Why retail investors favor Beam Therapeutics Inc. stockJuly 2025 Trends & Free Low Drawdown Momentum Trade Ideas - newser.com
Finanzdaten der Beam Therapeutics Inc-Aktie (BEAM)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):